This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
EU Joint Clinical Assessment (JCA)
EU Joint Clinical Assessment (JCA)
The Joint clinical assessment (JCA) is a centralized assessment of the relative effectiveness and the relative safety of a health technology. It should allow national reimbursement authorities to restrict their efforts to the appraisal and the reimbursement resolution.
The JCA will be mandatory for new oncology medicines and advanced therapies for which a marketing authorization application is submitted from January 2025. New orphan medicines will be in scope from 2028 and all other new medicines from 2030. As of May 2024, timelines remain unclear for invasive medical devices.